Vesugen
Muscle/RecoveryKhavinson vascular tripeptide / researchExperimental
Short vascular bioregulator (often Lys-Glu-Asp). Not FDA-approved.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- ≈390.4 g/mol
- Half-life
- Not established (limited public PK data; primarily research context)
- Unit
- mg
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Frequency
- Once daily (typical research pattern)
- Last updated
- 8/23/2026
- Targets
- Vascular endothelium (proposed)
Overview
Short vascular bioregulator (often Lys-Glu-Asp). Not FDA-approved.
Protocol
- Dosage Range
- 5-20 mg daily (research context; not clinically established)
- Frequency
- Once daily (typical research pattern)
- Cycle
- 10-30 days common in bioregulator protocols (research context)
- Administration Route
- Oral or sublingual (common commercial formats); injectable research use exists by supplier
- Reconstitution Guide
- If lyophilized: reconstitute with bacteriostatic water per lab SOP (research only)
Science
Mechanism of Action
Proposed endothelial-gene modulation in older papers. Not validated in modern RCTs.
Targets
Vascular endothelium (proposed)
Studies
- Khavinson bioregulators— Journal/year not available
Benefits
Vascular-bioregulator research category
Potential Side Effects
- Not characterized
References
- PMID 15587334External link · Year —